The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization

Gynecological Endocrinology

Volumn 23, Issue 2, 2007, Pages 72-75

  Orvieto, Raoul ^a   Zohav, Efraim ^b   Scharf, Shimon ^b   Rabinson, Jacob ^b   Meltcer, Simion ^b   Anteby, Eyal Y ^b   Homburg, Roy ^b  

^a BARZILAI MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Estradiol oocyte ratio; Gonadotropin releasing hormone agonist; Gonadotropin releasing hormone antagonist; Outcome of in vitro fertilization; Pregnancy

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; HUMAN; OOCYTE; OUTCOME ASSESSMENT; OVARY; OVARY FOLLICLE; PREGNANCY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STIMULATION;

ADULT; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OOCYTES; OVARIAN FOLLICLE; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPTORELIN;

EID: 33947572247     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590601137137     Document Type: Article

References (19)

1. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 2001;265:175-182.
2. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002;17:874-885.
3. Daya S. GnRH-agonists versus antagonists in assisted reproduction - a systematic review. Abstract book of the 8th International Symposium on GnRH-analogues in Cancer and Human Reproduction 2005;A100.
4. Orvieto R, Rabinson J, Meltzer S, Homburg R, Anteby E, Zohav E. GnRH agonist versus GnRH antagonist in ovarian stimulation: is the emperor naked? Clin Exp Obstet Gynecol 2006;33:197-199.
5. Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005;83:1607-1611.
6. Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German National IVF Registry. Hum Reprod 2005;20:2373-2375.
7. Loumaye E, Engrand P, Howles CM, O'Dea L. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril 1997;67:889-899.
8. 2:oocyte ratio in women undergoing IVF and tubal ET. Correlation with a decrease in the implantation rate. J Reprod Med 2001;46:434-438.
9. Orvieto R, Bar-Hava I, Yoeli R, Ashkenazi J, Rabinerson D, Bar J, Fisch B. Results of in vitro fertilization in women aged 43-45 years. Gynecol Endocrinol 2004;18:75-78.
10. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15:526-531.
11. European Orgalutran Study Group. Treatment with the gonadotrophin releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490-1498.
12. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000;73:314-320.
13. European-Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644-651.
14. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38-45.
15. Fleischer AC, Daniell JF, Rodier J, Lindsay AM, James AE Jr. Sonographic monitoring of ovarian follicular development. J Clin Ultrasound 1981;9:275-280.
16. Tarlatzis BC, Laufer N, DeCherney AH. The use of ovarian ultrasonography in monitoring ovulation induction. J In Vitro Fert Embryo Transf 1984;1:226-232.
17. Ben Shlomo I, Geselevich J, Shalev E. Can we abandon routine evaluation of serum estradiol levels during controlled ovarian hyperstimulation for assisted reproduction? Fertil Steril 2001;76:300-303.
18. Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 2003;18:665-667.
19. Billig H, Furuta F, Hsueh AIW. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 1993;133:2204-2212.